GLP-1 Evidence

Not medical advice. A record of published research and our assessments of it. The limits

Oral Adverse Effects of Semaglutide Therapy: A Narrative Review

Design
Pharmacovigilance
Drugs
Semaglutide
Assessment
Facts extracted automatically · reviewed by Carrie Schluter, Nov 5, 2026 · added Sep 13, 2026

This study was added automatically, and its details were extracted by machine rather than read off the paper by a person. Carrie Schluter has reviewed the record, but that review did not re-extract those details, so the collection still publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.

01Source

The source, as retrieved

Abstract

[OBJECTIVE] Semaglutide, a glucagon-like peptide-1-receptor agonist, is widely used for the management of type-2 diabetes mellitus and obesity. Despite its increasing clinical use, the drug's oral adverse effect profile remains inadequately characterized. This narrative review aimed to analyze the current evidence on semaglutide-associated oral adverse effects, with emphasis on mechanistic pathways, integration of pharmacovigilance and clinical data, and emerging implications for oral health and dental practice. [METHODS] A comprehensive literature search was conducted across PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar. Keywords related to semaglutide and oral adverse effects were used. Eligible studies included clinical trials, pharmacovigilance analyses, observational studies, case reports, and preclinical research reporting oral adverse effects or relevant mechanistic insights. Studies lacking oral health correlates were excluded. Findings were narratively reviewed in accordance with Scale for the Assessment of Narrative Review Articles guidelines. [RESULTS] Xerostomia or hyposalivation is the most consistently reported oral adverse effect, although its prevalence varies across studies. However, xerostomia often occurs secondarily to gastrointestinal symptoms including nausea, reduced oral intake, and delayed gastric emptying. Additional manifestations included dysgeusia, dry throat, oral paresthesia or hypoesthesia, halitosis, frothy saliva, and increased dental caries. Pharmacovigilance data show significant signals for dry mouth and altered taste. Case-series confirm semaglutide-associated hyposalivation. Limited evidence suggests increased susceptibility to oral candidiasis. Early experimental and observational data indicate potential modulatory effects on inflammation, tissue repair, and bone metabolism. [CONCLUSION] Semaglutide therapy is associated with oral adverse effects, mainly xerostomia and sensory disturbances, which may compromise oral health. Awareness of these outcomes highlights the need for interdisciplinary oral health monitoring.

Where this record came from

SourceRetrievedIdentifier
pubmedSep 13, 202642730115
first ingestion
pubmedSep 13, 202642730115
duplicate matched on doi
pubmedSep 13, 202642730115
duplicate matched on doi
pubmedSep 20, 202642730115
duplicate matched on doi
pubmedSep 20, 202642730115
duplicate matched on doi
pubmedSep 20, 202642730115
duplicate matched on doi
pubmedSep 27, 202642730115
duplicate matched on doi
pubmedSep 27, 202642730115
duplicate matched on doi
pubmedSep 27, 202642730115
duplicate matched on doi
owner-reviewNov 6, 2026
reviewed_by set to Carrie Schluter (2026-11-05) on the owner's own confirmation. The assessment is unchanged and still the auto-classifier's, so its extracted values stay withheld under the 2026-10-18 decision.